Autopsy report · NCT03245619

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults

“The study was terminated as relationship between GSK3335065 and ventricular tachycardia could not be excluded.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Pancreatitis, Acute Necrotizing

Interventions

GSK3335065; Placebo

Participants

18

Sites

1

Countries

United Kingdom

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.